Get access

Cervical Epidermal Growth Factor-Receptor (EGF-R) and Serum Insulin-Like Growth Factor II (IGF-II) Levels are Potential Markers for Cervical Cancer

Authors

  • SUBBI P. MATHUR,

    1. The Division of Research, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina
    Search for more papers by this author
  • RAJESH S. MATHUR,

    1. The Division of Research, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina
    Search for more papers by this author
  • ROGER C. YOUNG

    1. The Division of Research, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina
    Search for more papers by this author

Address reprint requests to Subbi P. Mathur, Ph.D., Professor, Department of Obstetrics and Gynecology, Medical University of South Carolina, 95 Jonathan Lucas Street, Suite 634, P.O. Box 250619, Charleston, SC 29425.

E-mail: mathurs@musc.edu

Abstract

PROBLEM: To ascertain if cervical epithelial epidermal growth factor receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer.
METHOD OF STUDY: We tested cervical biopsies obtained from 18 controls, 3 women with cervical intraepithelial neoplasia (CIN) I, 17 women with CIN II and III, and 12 women with cervical cancer for EGF-R using a quantitative immunofluorescent antibody assay. We measured serum IGF-II levels using an enzyme-linked immunosorbent assay in 20 controls, 26 CIN patients, 12 with cervical cancer before therapy, 5 with cervical cancer for <1 year, and 9 others ≥1 year after therapy.
RESULTS: The levels of cervical EGF-R in women with CIN and cervical cancer were significantly higher (P<0.05 for CIN I; P<0.001 for patients with CIN II and III or cervical cancer) than in controls. Women with cervical cancer (P<0.001 vs. controls) or advanced CIN (P=0.03) had elevated levels of serum IGF-II, while the women with CIN I had levels similar to controls. Women with cervical cancer in the post-therapy period had significantly lower serum IGF-II levels than the women with cervical cancer before therapy (P<0.001).
CONCLUSION: Cervical epithelial EGF-R and serum IGF-II levels may be used for the diagnosis and prognosis of cervical cancer.

Ancillary